



Pharma Finance 2007

ROMA - ITALY - MAY 10-11

5TH ANNUAL PARTNERING CONFERENCE

Market Data (AS OF MAY 1, 2007)



Symbol	CYTR
Exchange	NASDAQ
Current Price	\$4.86
Shares Outstanding	76.8M
Market Capital	\$374M
52wk RANGE	\$0.87-\$5.49
Average Volume	3,012,730
YTD % Change	112%

COMPANY FACT SHEET



CytRx Corporation
 11726 San Vicente Blvd.
 Suite 650
 Los Angeles, CA 90049
 (310) 829-5648

www.cytrx.com



David Haen
 Director of BD

FINANCIAL HIGHLIGHTS (YEAR ENDING DEC 31ST, 2006)

Net Revenue:	2.07M	Earnings per Share:	(0.25)
Net Income:	(17.24M)	Weighted Average:	68.1M

CONFERENCE OBJECTIVES

Increase CytRx's European shareholder base. Seeking in-licensing and collaboration opportunities in the field of cell protection. Meet potential licensees for Molecular Chaperone Co-Inducers including arimoclomol and iroxanadine. Find licensees for HIV vaccine.

RECENT DEVELOPMENTS

May 1, 2007

CytRx Contributes \$15 Million Net to Majority-Owned RNAi Subsidiary RXi Pharmaceuticals

April 20, 2007

CytRx Completes \$37.0 Million Private Placement.

April 4, 2007

CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies

PRODUCT AND PRODUCT CANDIDATE PIPELINE

Chaperone Co-Induction

CytRx owns three clinical-stage compounds based on its small molecule "molecular chaperone" co-induction technology, as well as a targeted library of 500 small molecule drug candidates that may be used to screen for new drug candidates. The three small molecule drugs (arimoclomol, iroxanadine and bimoclomol) provide cellular protection from abnormal proteins by activating molecular "chaperone" proteins that can repair or degrade the damaged proteins that are believed to cause many diseases, including ALS and diabetes.

RNAi - Drug Discovery and Therapeutics

Starting with over 2000 candidate genes regulated in diabetes and obesity, CytRx is using its proprietary high throughput RNAi based screening technology in metabolic cells to rapidly validate numerous drug targets involved in the most critical pathways which regulate metabolism. With access to years of genomics data highlighting key regulatory targets in new and existing

pathways in obesity and type 2 diabetes, CytRx has a clear advantage to be the first company to develop therapeutics against the most significant targets emerging from the complete human genome sequence. By applying its proprietary structure based high throughput medicinal chemistry platform and its RNAi chemistry and delivery technology, CytRx is rapidly developing small molecule and RNAi therapeutics against prime-time and novel targets.

DNA/Protein Vaccine

The Company's HIV vaccine technology, licensed from Universtiy Massachusetts Medical School and Advanced Bioscience Laboratories, is based on a unique mixture of human HIV-1 primary isolates from several genetic subtypes of HIV. This naked DNA vaccine approach has the potential advantages of maintaining efficacy despite the high mutation rate of HIV, a broader immune response against divergent HIV-1 glycoproteins and the possible ability to neutralize a wide spectrum of HIV-1 viruses.

Company Description

CytRx Corporation, is a biopharmaceutical company engaged in the development of high-value therapeutics utilizing its core technologies in small molecule drugs, RNAi drug discovery and DNA vaccines. CytRx is developing products based on three unique platforms: small molecule chaperone amplification, RNAi technology, and DNA vaccines in a variety of therapeutic indications including ALS, obesity, type 2 diabetes, HIV and cardiovascular disease.